GAVI recently highlighted new data showing that the typhoid conjugate vaccination (TCV) induces a good immunological response in children and does not interact with the measles-rubella (MR) vaccine when administered at the same time.

This immune response data were nested within a vaccination effectiveness research released in 2021, which revealed that TCV had an 84% efficacy in preventing typhoid among children and may be effective for at least three years.

99% of babies who received TCV with MR vaccine developed protective antibody levels in their blood 28 days after immunization, and 68% sustained this protection for 2-3 years. 

This research reveals that TCV and MR vaccinations do not conflict with each other and may thus be administered simultaneously.

The latest study findings add to the growing body of data that TCV protects African children's lives.

The findings of the Malawi research are consistent with those of earlier TCV immunogenicity studies conducted in India, Nepal, Bangladesh, and Burkina Faso, which found that TCV may be safely co-administered with other routine vaccinations.


The World Health Organization (WHO) advises that all children younger than 12 months of age get routine TCV vaccination in areas with a high prevalence of typhoid and/or drug-resistant typhoid.


Typhoid fever is a potentially fatal infection caused by the Salmonella Typhi bacterium.

Typhoid fever affects an estimated 11 to 21 million individuals worldwide.

Each year, around 350 persons in the United States are diagnosed with typhoid fever.

Furthermore, the  CDC recommends vaccination for those traveling to areas where typhoid fever is widespread, such as South Asia, particularly India, Pakistan, and Bangladesh.


In the United States, there are two typhoid fever vaccinations available:

  • Oral vaccine: Can be given to persons above the age of six. It consists of four tablets taken every other day for at least one week before travel.
  • Injectable vaccine: Can be administered to persons above the age of two, and should be given at least two weeks before travel.


Typhoid vaccinations, on the other hand, lose efficacy over time.

The injectable vaccination has to be boosted every two years, whereas the oral vaccine needs to be boosted every five years.

If you have already been immunized, ask your doctor or pharmacist if it is time for a booster vaccine before traveling to high-risk locations.

Furthermore, using antibiotics will not prevent typhoid fever; they only assist treat it, according to the CDC. People who do not receive sufficient antibiotic therapy may experience fever for weeks or months and develop other health issues.